News

A new clinical trial being conducted in the United Kingdom is recruiting participants to study the early stages of chronic obstructive pulmonary disease (COPD), and identify people at risk of developing the disease. This will be the first study to track changes in lung function over time before COPD…

Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with chronic obstructive pulmonary disease (COPD). The ongoing two-part Phase 2 trial, called SG015 (2017-003679-75), is evaluating the safety and effectiveness of SNG001 to prevent acute worsening of COPD symptoms…

Inhaled corticosteroids, which are typically used to treat common respiratory diseases such as chronic obstructive pulmonary disease (COPD), are associated with increased bacterial infections and can lead to worse health outcomes, a study in mice has found. Most exacerbations experienced by patients with asthma and COPD are caused by viral infections.

Pulmatrix‘s branded generic of Spiriva HandiHaler, called PUR0200, was shown to promote similar improvements in lung function in patients with chronic obstructive pulmonary disease (COPD), but at significantly lower doses than Spiriva, according to a Phase 1 clinical trial. The study reporting the findings is titled “The pharmacokinetics,…

The surgical removal of tonsils and adenoids, a common procedure in children, has been linked to an increased risk of respiratory infectious diseases, particularly chronic obstructive pulmonary disease (COPD), a new study reports. The study, “Association of Long-Term Risk of Respiratory, Allergic, and Infectious Diseases With Removal of Adenoids…

A patient-satisfaction survey found that the uni-flo2 single-nasal cannula system (Uni-flo2) is considered to be comfortable, stable and secure by 98 percent of those who responded, the system’s developers reported in a press release. Uni-flo2 is designed to ensure continuous oxygen flow, equivalent to the low-flow, dual-pronged cannula…

The investigational monoclonal antibody Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), top-line results of the Phase 3 TERRANOVA trial have shown. The disappointing results follow previously announced data from the Phase 3 GALATHEA trial that also showed the candidate…

A newly developed tool can predict patients with chronic obstructive pulmonary disease (COPD) who are at a high risk of hospitalization due to a disease flare-up, according to a study. The new Laboratory-based Intermountain Validated Exacerbation, or LIVE, score identifies patients who may benefit from early intervention to avoid hospitalization…

Combining home oxygen therapy (HOT) with home noninvasive ventilation (HMV) could be more effective and less expensive than HOT alone for certain patients with chronic obstructive pulmonary disease (COPD), a study suggests. Sponsored by the health technology company Royal Philips, the study offers an economic analysis showing potential…

The Zephyr Endobronchial Valve, Pulmonx’s minimally invasive treatment for severe emphysema, was recently found to improve breathing, quality of life, and activity for patients in a U.S. clinical trial called LIBERATE. The treatment met all of the trial’s primary and secondary endpoints, or goals, after one year. Emphysema is a…